Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 25/100

NovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18, 2023 deadline

Monday, June 26, 2023 2 min read
Key Takeaway: NovoCure Limited is facing legal action from investors who allege that the company made false statements regarding its LUNAR study data. The complaint claims that important information was concealed, casting doubt on the study's reliability and its implications for regulatory approval. Affected investors are encouraged to contact the Portnoy Law Firm for a complimentary legal evaluation. The outcome of this case could have significant effects on NovoCure's regulatory standing and overall operations.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors are considering legal action due to alleged misleading statements by NovoCure.
  • The lawsuit claims that the company concealed critical information about the LUNAR study data.
  • The reliability of the LUNAR study data, which is important for regulatory processes, has been called into question.
  • Allegations suggest that statements made by NovoCure could adversely impact their regulatory prospects and operations.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors that a lawsuit filed on behalf of investors that purchased NovoCure securities between January 5, 2023 to June 5, inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint asserts that the defendants engaged in false and/or deceptive statements and/or omitted important information, claiming the following:
The Company concealed the true nature of the LUNAR study data, which involved a relatively small percentage of participants who were receiving standard of care therapy.
Consequently, the reliability of the data in demonstrating clinical efficacy was significantly compromised.
The disclosure of this information had a reasonable likelihood of negatively affecting the Company's regulatory prospects and overall operations.
As a result, the Company's public statements made during the relevant times were materially false and misleading.
The allegations suggest that the defendants misrepresented the LUNAR study data and its impact, leading to potential negative consequences for the Company's regulatory prospects and operations.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
Attorney Advertising

Tags

Frequently Asked Questions

How can NovoCure investors recover their losses?

Investors can contact the Portnoy Law Firm for a complimentary case evaluation.

What is the Class Period for the NovoCure lawsuit?

The Class Period runs from January 5, 2023, to June 5, 2023.

What allegations are made against NovoCure?

The complaint alleges false statements regarding the LUNAR study data.

Who can investors contact for more information?

Investors can reach attorney Lesley F. Portnoy at 844-767-8529 or via email.

What prior successes does the Portnoy Law Firm have?

The firm has recovered over $5.5 billion for investors affected by corporate wrongdoing.

Tags: NVCR Viatris Investor Conferences Healthcare NovoCure LUNAR study investors Portnoy Law Firm
Last updated: Jun 26, 2023